Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
Gene Ther ; 9(20): 1369-78, 2002 Oct.
Article in English | MEDLINE | ID: mdl-12365002

ABSTRACT

Viral DNA vaccines encoding the glycoprotein B (gB) of cytomegalovirus provide partial protective immunity upon challenge with infectious virus. Although it is known that type I IFN can stimulate the adaptive immune response, their direct use in vaccines has been limited. Here we show that coimmunisation of type I IFN and gB CMV DNA constructs enhances protective immunity in mice. In vivo expression of IFN transgenes ranged from 1.2 to 2.0 x 10(4) IU/g tibialis anterior muscle. Viral titre in major target organs and the severity of acute CMV-induced myocarditis was reduced preferentially with either IFN-alpha 9 or IFN-beta, but not with IFN-alpha 6, coimmunisation. However, all IFN subtypes investigated markedly reduced chronic myocarditis in gB-vaccinated mice. The early antiviral IgG1 and IgG2a titres were enhanced with IFN-beta coimmunisation. TNF and IL-10 was increased in response to MCMV infection in mice coimmunised with IFN subtypes and viral gB DNA. Indeed T cells from IFN-inoculated mice reduced myocarditis upon in vivo transfer. These results suggest that select type I IFNs may act as a natural adjuvant for the immune response against CMV infection. Type I IFN DNA coimmunisation may provide increased efficacy for viral vaccines and subsequently modulate post-viral chronic inflammatory disorders.


Subject(s)
Cytomegalovirus Infections/immunology , Genetic Therapy/methods , Interferon Type I/genetics , Myocarditis/immunology , Viral Envelope Proteins/genetics , Viral Vaccines/administration & dosage , Animals , Male , Mice , Mice, Inbred BALB C , Muromegalovirus , Viral Fusion Proteins/genetics
2.
Am J Psychiatry ; 155(3): 337-43, 1998 Mar.
Article in English | MEDLINE | ID: mdl-9501742

ABSTRACT

OBJECTIVE: The CNS metabolic response to a neuroleptic challenge in treatment-responsive and nonresponsive schizophrenic patients was measured in order to examine the relation between treatment outcome and the capacity to alter neurochemical function in response to acute receptor blockade. METHOD: Positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG) were used to measure regional cerebral metabolism in seven schizophrenic patients judged to have been responsive to drug treatment previously and seven nonresponsive schizophrenic patients after a drug-free period of at least 3 weeks (baseline) and again 12 hours after administration of 5.0 mg of haloperidol. RESULTS: The haloperidol challenge caused widespread decreases in absolute metabolism in the nonresponsive patients but not the responsive patients. These group differences reflect the findings on the second (challenge) scans, since metabolic values at baseline were not statistically different in the two groups. The pattern of decreased metabolic activity in the nonresponders after the haloperidol challenge is similar to that previously observed in normal subjects. CONCLUSIONS: The metabolic response to drug challenge separates treatment responders from nonresponders and normal subjects. The results suggest that subtyping of schizophrenia (and other psychiatric disorders) can be achieved by measuring the physiologic response to a pharmacologic challenge in vivo with chemical brain-imaging techniques.


Subject(s)
Antipsychotic Agents/pharmacology , Brain/drug effects , Glucose/metabolism , Haloperidol/pharmacology , Schizophrenia/drug therapy , Adult , Algorithms , Antipsychotic Agents/therapeutic use , Brain/diagnostic imaging , Brain/metabolism , Brief Psychiatric Rating Scale , Cerebellum/drug effects , Cerebellum/metabolism , Corpus Striatum/drug effects , Corpus Striatum/metabolism , Dose-Response Relationship, Drug , Female , Fluorodeoxyglucose F18/metabolism , Haloperidol/administration & dosage , Humans , Magnetic Resonance Imaging , Male , Neocortex/drug effects , Neocortex/metabolism , Receptors, Dopamine D2/drug effects , Receptors, Dopamine D2/metabolism , Schizophrenia/classification , Schizophrenia/metabolism , Severity of Illness Index , Tomography, Emission-Computed , Treatment Outcome
3.
Clin Neuropharmacol ; 19(5): 371-89, 1996 Oct.
Article in English | MEDLINE | ID: mdl-8889281

ABSTRACT

Functional brain imaging with positron emission tomography (PET) has opened up new avenues for the investigation of possible functional disturbances related to psychiatric disease as well as pharmacodynamic assessment of drug treatment in vivo. Different strategies to study pharmacologic effects on the brain have been developed in recent years. The basic methods are to measure (a) blood flow or glucose metabolism, (b) parameters of specific receptor binding, or (c) neurotransmitter metabolism. Each of these can be performed either in a resting state or after perturbation with a pharmacologic challenge. Our group has developed a general strategy for investigating pharmacologic effects on brain function: (a) determining indirect drug-induced metabolic changes with fluorodeoxyglucose PET and (b) characterizing functional interactions of neurotransmitter systems by assaying drug-induced displacement of specific receptor ligands. These study designs reflect a paradigm shift where functional coupling of brain regions and interaction of different neurotransmitter systems are seen as the basis for a multitransmitter hypothesis of schizophrenia. In this view, any disturbance in the self-regulatory process is reflected in the loss of functional interaction between systems. An overview of recent studies and their possible clinical importance will be presented.


Subject(s)
Brain/diagnostic imaging , Neurotransmitter Agents/physiology , Animals , Brain/drug effects , Humans , Tomography, Emission-Computed
4.
Psychiatry Res ; 60(2-3): 91-9, 1996 Mar 29.
Article in English | MEDLINE | ID: mdl-8723299

ABSTRACT

Positron emission tomography and the fluorodeoxyglucose method were used to measure regional brain metabolism before and 2 h after haloperidol (5 mg, i.m.) in 11 young normal men. These data were compared with measures obtained from nine previously studied normal men who had received no drug intervention. Although a previously published study had demonstrated significantly decreased metabolism in whole brain, neocortex, limbic cortex, thalamus, and caudate nucleus 12 h after a 5-mg dose of haloperidol, the present 2-h study did not show significant metabolic changes despite the fact that significant extrapyramidal effects occurred. Taken together, these studies demonstrate differences in the temporal organization of behavioral and metabolic responses to haloperidol challenge.


Subject(s)
Antipsychotic Agents/pharmacology , Blood Glucose/metabolism , Brain/drug effects , Energy Metabolism/drug effects , Haloperidol/pharmacology , Tomography, Emission-Computed , Adult , Brain/physiology , Deoxyglucose/analogs & derivatives , Deoxyglucose/metabolism , Energy Metabolism/physiology , Extrapyramidal Tracts/drug effects , Fluorodeoxyglucose F18 , Humans , Injections, Intramuscular , Male , Neurologic Examination/drug effects , Receptors, Dopamine/drug effects , Receptors, Dopamine/physiology , Receptors, Dopamine D2/drug effects , Receptors, Dopamine D2/physiology , Reference Values
5.
Am J Psychiatry ; 151(5): 681-6, 1994 May.
Article in English | MEDLINE | ID: mdl-8166309

ABSTRACT

OBJECTIVE: Positron emission tomography and the fluorodeoxyglucose (FDG) method were used to determine the brain's metabolic response to neuroleptic challenge in a normal, disease-free state. METHOD: FDG measurements were obtained before and 12 hours after administration of 5 mg of haloperidol to 12 young normal men. These values were compared with test-retest FDG measures obtained from nine normal male control subjects who received no drug intervention. RESULTS: After haloperidol administration, the haloperidol subjects showed significantly lower glucose utilization in the neocortex, limbic cortex, thalamus, and caudate nucleus but not in the putamen or cerebellum. After adjustment for global effects, significant reductions were still evident in the frontal, occipital, and anterior cingulate cortex, whereas the putamen and cerebellum showed significant increases. CONCLUSIONS: This study, measuring the brain's metabolic response to acute receptor blockade, is a first step in the development of an assay of CNS pharmacological activity. By determining the response to neuroleptic challenge in a normal state, the study establishes a comparison group for determining response to challenge in various psychiatric conditions.


Subject(s)
Brain/metabolism , Glucose/metabolism , Haloperidol/pharmacology , Adult , Brain/diagnostic imaging , Brain/drug effects , Cerebellum/drug effects , Cerebellum/metabolism , Cerebral Cortex/drug effects , Cerebral Cortex/metabolism , Deoxyglucose/analogs & derivatives , Deoxyglucose/metabolism , Fluorodeoxyglucose F18 , Humans , Limbic System/drug effects , Limbic System/metabolism , Male , Mental Disorders/diagnosis , Mental Disorders/metabolism , Putamen/drug effects , Putamen/metabolism , Thalamus/drug effects , Thalamus/metabolism , Tomography, Emission-Computed
6.
Eur Arch Psychiatry Clin Neurosci ; 244(3): 115-25, 1994.
Article in English | MEDLINE | ID: mdl-7803524

ABSTRACT

Positron emission tomography (PET) and the deoxyglucose method were used to measure cerebral metabolism in 14 normals and 13 schizophrenics at rest and during performance of simple and complex finger-movement sequences. The normals, but not the schizophrenics, showed significant metabolic activation in mesial frontal and contralateral sensorimotor and premotor regions during the complex movement. The relative metabolism of schizophrenics was significantly lower than normal in frontal regions and higher than normal in thalamus and basal ganglia under all scanning conditions. The results suggest that schizophrenics may have a brain dysfunction which limits their capacity to produce a focal metabolic response to stimulation in several functionally distinct brain regions.


Subject(s)
Attention/physiology , Blood Glucose/metabolism , Brain/diagnostic imaging , Energy Metabolism/physiology , Motor Skills/physiology , Schizophrenia/diagnostic imaging , Tomography, Emission-Computed , Adult , Arousal/physiology , Brain Mapping , Cerebral Cortex/diagnostic imaging , Deoxyglucose/metabolism , Humans , Male , Mental Recall/physiology , Middle Aged , Serial Learning/physiology
7.
Psychiatry Res ; 40(2): 115-24, 1991 Oct.
Article in English | MEDLINE | ID: mdl-1763142

ABSTRACT

This study compares the effects of two neuroleptic drugs with different pharmacologic characteristics (thiothixene and haloperidol) on cerebral glucose utilization in chronic schizophrenic inpatients. Positron emission tomographic (PET) scans were obtained from all subjects in a neuroleptic-free condition and again after 4-6 weeks of neuroleptic treatment. Eight subjects were treated with thiothixene and 12 with haloperidol. Thiothixene and haloperidol had different metabolic effects. For example, all thiothixene-treated subjects showed increased whole brain glucose utilization; all but one haloperidol-treated subject showed decreased utilization. Different patterns of relative prefrontal and striatal metabolism were also observed. These results highlight the importance of controlling for the effects of neuroleptic treatment and indicate the difficulty of interpreting data from studies with complex or poorly defined drug regimens.


Subject(s)
Blood Glucose/metabolism , Brain/drug effects , Brain/diagnostic imaging , Energy Metabolism/drug effects , Haloperidol/therapeutic use , Schizophrenia/diagnostic imaging , Schizophrenia/drug therapy , Schizophrenic Psychology , Thiothixene/therapeutic use , Tomography, Emission-Computed , Adult , Basal Ganglia/diagnostic imaging , Basal Ganglia/drug effects , Basal Ganglia/physiopathology , Brain/physiopathology , Brain Mapping , Chronic Disease , Dose-Response Relationship, Drug , Energy Metabolism/physiology , Frontal Lobe/diagnostic imaging , Frontal Lobe/drug effects , Frontal Lobe/physiopathology , Haloperidol/pharmacokinetics , Humans , Male , Middle Aged , Schizophrenia/physiopathology , Thiothixene/pharmacokinetics
8.
Psychiatry Res ; 40(1): 11-20, 1991 May.
Article in English | MEDLINE | ID: mdl-1946838

ABSTRACT

Positron emission tomography (PET) and the deoxyglucose method were used to determine the test-retest stability of regional cerebral glucose metabolism in 8 male schizophrenic patients and 11 normal control subjects, scanned twice under baseline (resting) conditions. Normal and schizophrenic subjects showed comparable stability of regional metabolism. When the regional values were scaled to compensate for the effects of changes in whole brain metabolism, the resulting mean regional changes were reduced to about 1-2% in both groups. This study demonstrates that the baseline resting state is an appropriate reference state for schizophrenic subjects in deoxyglucose PET experiments.


Subject(s)
Blood Glucose/metabolism , Energy Metabolism/physiology , Schizophrenia/diagnostic imaging , Schizophrenic Psychology , Tomography, Emission-Computed , Adult , Arousal/physiology , Brain/diagnostic imaging , Deoxyglucose/analogs & derivatives , Deoxyglucose/metabolism , Fluorodeoxyglucose F18 , Humans , Male , Reference Values
9.
J Cereb Blood Flow Metab ; 8(4): 502-12, 1988 Aug.
Article in English | MEDLINE | ID: mdl-3260593

ABSTRACT

Positron emission tomography with 11C-2-deoxyglucose was used to determine the test-retest variability of regional cerebral glucose metabolism in 22 young normal right-handed men scanned twice in a 24-h period under baseline (resting) conditions. To assess the effects of scan order and time of day on variability, 12 subjects were scanned in the morning and afternoon of the same day (a.m.-p.m.) and 10 in the reverse order (p.m.-a.m.) with a night in between. The effect of anxiety on metabolism was also assessed. Seventy-three percent of the total subject group showed changes in whole brain metabolism from the first to the second measurement of 10% or less, with comparable changes in various cortical and subcortical regions. When a scaling factor was used to equate the whole brain metabolism in the two scans for each individual, the resulting average regional changes for each group were no more than 1%. This suggests that the proportion of the whole brain metabolism utilized regionally is stable in a group of subjects over time. Both groups of subjects had lower morning than afternoon metabolism, but the differences were slight in the p.m.-a.m. group. One measure of anxiety (pulse at run 1) was correlated with run 1 metabolism and with the percentage of change from run 1 to run 2. No significant run 2 correlations were observed. This is the first study to measure test-retest variability in cerebral glucose metabolism in a large sample of young normal subjects. It demonstrates that the deoxyglucose method yields low intrasubject variability and high stability over a 24-h period.


Subject(s)
Brain/metabolism , Glucose/metabolism , Adolescent , Adult , Anxiety/physiology , Brain/diagnostic imaging , Circadian Rhythm , Humans , Male , Reference Values , Rest , Tomography, Emission-Computed
10.
Brain Lang ; 32(1): 1-18, 1987 Sep.
Article in English | MEDLINE | ID: mdl-3498529

ABSTRACT

This study examines the effect of different behavioral conditions on patterns of correlation between regional cerebral metabolic rates for glucose. Cerebral glucose metabolism was determined with positron emission tomography and (11C)-deoxyglucose in 29 normal subjects between the ages of 23 and 55. Seventeen subjects were studied in an unstimulated (resting) condition and 12 subjects during a phoneme monitoring language stimulation. Partial correlation coefficients, controlling for whole brain glucose metabolism, were calculated for pairs of metabolic rates in 14 cortical and 2 subcortical regions. Both stimulated and unstimulated subjects showed statistically significant correlations between left and right hemisphere homologs. The stimulated subjects also showed significant within-hemisphere correlations between left but not right hemisphere regions. These included left perisylvian regions classically associated with language functions (left inferior frontal, left superior temporal and left transverse temporal cortical regions) as well as other regions. Significant correlations between left regions and a right superior temporal region were also found. In general, these findings show a pattern of cross-hemisphere symmetry at rest and of hemisphere asymmetry during stimulation. Moreover, the asymmetry observed during stimulation appears to be superimposed upon a pattern of cross-hemisphere symmetry similar to that observed in the unstimulated state.


Subject(s)
Blood Glucose/metabolism , Cerebral Cortex/metabolism , Speech Perception/physiology , Tomography, Emission-Computed , Adult , Attention/physiology , Deoxyglucose/metabolism , Dominance, Cerebral/physiology , Humans , Male , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...